Clinical Trial Update: An Open Label, Single Arm, Multicenter Phase II Study of BYL719 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck Who Failed to Respond to Platinum-based Therapy. [Phase 2]

View source ↗

Summary

Open-label, single-arm Phase II trial evaluating BYL719 (alpelisib) in recurrent or metastatic head and neck squamous cell carcinoma after platinum therapy; cur…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• BYL719 (alpelisib)

Snippet

Sponsor: Yonsei University | Conditions: Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck | Phase 2 | Status: UNKNOWN